Since no correlation was found between the post-diagnostic use of β-blockers and breast cancer progression [103], these observations implied that the βAR-dependent mechanisms leading to recurrence might mainly affect early stages of metastatic dissemination. This evidence concerns the gene ADRB2 and breast carcinoma.